Article Details
Retrieved on: 2024-09-16 19:10:50
Tags for this article:
Click the tags to see associated articles and topics
Excerpt
Omalizumab is a monoclonal antibody that was approved for CSU in 2014. Besides that, phase 3 trials of dupilumab and remibrutinib have concluded. The ...
Article found on: www.dermatologytimes.com
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here